All In Biotech

Drug Trial Radar · NCT00970931

Hypertension Prevention in Pre-Hypertensive Individuals

Prevention of Hypertension in Patients With Pre-hypertension: PREVER-prevention Study

Last checked: Nov 20, 2026Latest source record: Feb 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 730 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

730

Actual

Start

Jul 2010

Primary completion

Sep 2014

Study completion Sep 2014

Sponsor

Lead sponsor
Hospital de Clinicas de Porto AlegreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Financiadora de Estudos e Projetos
First posted
Sep 3, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 30 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The incidence of hypertension in individuals with pre-hypertension was 80% in ten years in a study conducted in Southern Brazil. The effectiveness of non-drug interventions to prevent hypertension is low in the long term. It may be hypothesized that a population-based drug intervention could reduce relevantly the burden of hypertension and cardiovascular disease. Diuretics are at least as efficacious as other blood pressure-lowering drugs, are well tolerated, have longer duration of action and the advantage of very low cost to be used in a population intervention. Chlorthalidone is the more efficacious agent. Its main limitation is to induce hypokalemia in a proportion of patients, an adverse effect that can be antagonized by a potassium-sparing diuretic, as amiloride. A study with this objective is therefore recommendable in Brazil, in order to support a plan of precocious intervention in individuals with pre-hypertension. Such a study was demanded and funded by the Health and Technology Ministries in Brazil.

Conditions

  • Pre-hypertension
  • Hypertension
  • Cardiovascular Disease

Interventions

  • Chlorthalidone plus amilorideDrug

    Oral Chlorthalidone 12.5 mg plus amiloride 2.5 mg, once a day for 18 months

  • placeboDrug

    Oral placebo once a day, for 18 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of hypertension, by blood pressure ≥ 140/90 mmHg in individuals without diabetes or ≥ 135/85 mmHg in participants with diabetes.Time frame: 18 months
  2. Adverse events.Time frame: 18 months
  3. Development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKGTime frame: 18 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital de Clínicas de Porto Alegre, UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.